Immunotherapy cocktail shows promise for rare bone marrow cancer
NCT ID NCT02530463
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 28 times
Summary
This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with or without a chemotherapy drug (azacitidine) can help people with myelodysplastic syndromes (MDS), a type of bone marrow cancer. About 99 adults with MDS who either haven't been treated or whose previous treatment stopped working are taking part. The goal is to see if the combination shrinks tumors or improves blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.